Cresset Asset Management, LLC Editas Medicine, Inc. Transaction History

Cresset Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $126,283 - $247,813	-8,969 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$26.55 - $40.57 $499,272 - $762,918	-18,805 Reduced 67.71%	8,969 $238,000
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $74,573 - $138,513	-1,899 Reduced 6.4%	27,774 $1.14 Million
Q2 2021 Aug 10, 2021	SELL	$31.29 - $56.64 $43,899 - $79,465	-1,403 Reduced 4.51%	29,673 $1.68 Million
Q1 2021 May 12, 2021	BUY	$39.71 - $90.58 $565,549 - $1.29 Million	14,242 Added 84.6%	31,076 $1.31 Million
Q4 2020 Feb 11, 2021	SELL	$27.07 - $84.35 $21,006 - $65,455	-776 Reduced 4.41%	16,834 $1.18 Million
Q3 2020 Nov 13, 2020	BUY	$28.06 - $37.16 $256,496 - $339,679	9,141 Added 107.93%	17,610 $494,000
Q2 2020 Aug 04, 2020	BUY	$18.5 - $34.34 $156,676 - $290,825	8,469 New	8,469 $251,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $102M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cresset Asset Management, LLC with notifications on news.